Canopy Growth, Caredx, CytomX Therapeutics Among Healthcare Movers
Seeking AlphaMay 1 10:00 ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAkanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix (NASDAQ:NAOV) shares moved upwar
BenzingaMay 1 08:06 ET
BKKT, CETX and SWVL Among Mid-day Movers
Seeking AlphaApr 30 13:43 ET
Cyclacel CYCC Private Placement; NRx Pharmaceuticals NRXP Phase 2b/3 Failure
BioPharmCatalystApr 30 13:31 ET
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of H&E Equipment Services, Inc. (NASDAQ:HEES) fell sharply during Tuesday's session following mixed first-quarter results.H&E Equipment posted GAAP earnings of 71 cents per share, versus market
BenzingaApr 30 13:24 ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersAkili (NASDAQ:AKLI) stock moved upwards by 70.1% to $0.4 during Tuesday's regular session. The company's market cap stands at $31.4 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 51
BenzingaApr 30 12:31 ET
Why Is NRx Pharmaceuticals Stock Falling After Data From Suicidal Bipolar Depression Study
NRx Pharmaceuticals Inc (NASDAQ:NRXP) shares are down 23.1% at $2.73 at last check Tuesday.The stock plummet occurred on the heels of the company's latest study: the Phase 2b/3 trial of NRX-101 vs. Lu
BenzingaApr 30 11:46 ET
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals Among Healthcare Movers
Seeking AlphaApr 30 10:01 ET
Express News | NRx Pharmaceuticals Shares Are Trading Lower After the Company Announced Findings From Its Phase 2b/3 Trial of NRX-101 Vs. Lurasidone
BenzingaApr 30 09:19 ET
Express News | NRX Pharmaceuticals Shares Fall 20.9% Premarket as Depression Drug Fails to Reach Statistical Significance in Reducing Risk of Suicide in Trial
ReutersApr 30 08:49 ET
Express News | NRx Pharmaceuticals Says 'Both NRX-101 and Lurasidone, an Accepted Standard of Care in Bipolar Depression, Demonstrated Approximately 50% Reduction in Symptoms of Depression'
BenzingaApr 30 08:38 ET
Express News | NRx Pharmaceuticals Announces Findings In Phase 2b/3 Clinical Trial Of NRX-101 Vs. Lurasidone For Treatment Of Suicidal Bipolar Depression, Says Demonstrated A 'Promising, Though Not yet Statistically Significant 33% Reduction in Suicidality Together With
BenzingaApr 30 08:37 ET
Express News | NRX Pharmaceuticals Inc - Aims to Explore Role of NRX-101 as Primary Treatment for Much Larger Population of Patients With Bipolar Depression
ReutersApr 30 08:32 ET
Express News | NRX Pharmaceuticals Inc - Result Was Not Statistically Significant at Phase 2 SAMPLE Size but Met Study's Original Promising Zone Criteria
ReutersApr 30 08:31 ET
Express News | NRX Pharmaceuticals Inc: Both NRX-101 and Lurasidone Demonstrated About 50% Reduction in Symptoms of Depression
ReutersApr 30 08:31 ET
Express News | NRX Pharmaceuticals Inc - NRX-101 Show 75% Advantage in Relief From Akathisia Relative to Lurasidone
ReutersApr 30 08:31 ET
Express News | NRX Pharmaceuticals Inc - NRX-101 Is First Oral Antidepressant to Show 33% Advantage in Sustained Remission in Suicidality
ReutersApr 30 08:30 ET
Express News | NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Promising Findings in Phase 2B/3 Clinical Trial of NRX-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
ReutersApr 30 08:30 ET
NRx Pharmaceuticals, Inc. (NRXP) Advances While Market Declines: Some Information for Investors
Yahoo FinanceApr 19 18:00 ET
Benitec PIPE & Phase 1b/2a Data; NRX Pharmaceuticals NRXP Offering
BioPharmCatalystApr 18 15:46 ET
No Data
No Data